December 6, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) remained the top-selling drug in Japan in November, raking in sales of 11.2 billion yen on an NHI price basis, according to a monthly snapshot report released by market research firm Encise. Chugai Pharmaceutical’s cancer...read more